BioMed Research International / 2016 / Article / Tab 5 / Research Article
Prevalence of Extended Spectrum β -Lactamase and Antimicrobial Susceptibility Pattern of Clinical Isolates of Pseudomonas from Patients of Khyber Pakhtunkhwa, Pakistan Table 5 In vitro (%) susceptibility of ESBL and non-ESBL produced by Pseudomonas spp.
Antimicrobials ESBL producers Non-ESBL producers valueSusceptible (%) Resistant (%) Susceptible (%) Resistant (%) AML 14 (9.5) 134 (90.5) 36 (19.4) 150 (80.6) <0.018 AMC 24 (16.2) 124 (83.8) 58 (31.2) 128 (68.8) 0.0025 TZP 78 (52.7) 70 (47.3) 125 (67.2) 61 (32.8) <0.01 SCF 76 (51.4) 72 (48.6) 155 (83.3) 31 (16.7) <0.0001 CEC 21 (14.2) 127 (85.8) 50 (26.9) 136 (73.1) <0.007 CAZ 30 (20.3) 118 (79.7) 81 (43.5) 105 (56.5) <0.0001 CRO 22 (14.3) 126 (85.1) 99 (53.2) 87 (46.8) <0.0001 FEP 33 (22.3) 115 (77.7) 129 (69.4) 57 (30.6) <0.0001 SPX 62 (41.9) 86 (58.1) 124 (66.7) 62 (33.3) <0.0001 CIP 55 (37.2) 93 (62.8) 113 (60.8) 73 (39.2) <0.0001 ENX 43 (29.1) 105 (70.9) 74 (39.8) 112 (60.2) <0.05 GTX 55 (37.2) 93 (62.8) 94 (50.5) 92 (49.5) <0.01 MXF 80 (54.1) 68 (45.9) 116 (62.4) 70 (37.6) <0.13 E 36 (24.3) 112 (75.7) 28 (15.1) 158 (84.9) <0.325 CLR 66 (44.6) 80 (54.1) 76 (40.9) 110 (59.1) <0.43 MEM 128 (86.5) 20 (13.5) 176 (94.6) 10 (5.4) <0.0098 IPM 120 (81.1) 28 (18.9) 172 (92.5) 14 (7.5) <0.0018 CN 20 (13.5) 128 (86.5) 42 (22.6) 144 (77.4) <0.034 AK 75 (50.7) 73 (49.3) 141 (75.8) 45 (24.2) <0.0001 DO 9 (6.1) 139 (93.9) 25 (13.4) 161 (86.6) <0.0426